Drugs / RSV IMP 4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07516418 | Apr 2026 → Apr 2027 expected | avian influenza, respiratory syncytial virus infectious disease | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV IMP 4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07516418 ↗ |
| Modality | Vaccine | “different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen” NCT07516418 ↗ |
| Route | Intramuscular | “Route of administration: Intramuscular (IM) injection” NCT07516418 ↗ |